Nonexclusive license agreement covers testing of the NPMI gene mutation linked to the disease.

Xenomics granted Warnex Medical Laboratories a nonexclusive license in Canada to offer NPM1 testing as a laboratory service for the diagnosis, stratification, and monitoring of patients with acute myeloid leukemia (AML).

Xenomics holds exclusive rights to a discovery that showed that many AML patients have mutations in the NPM1 gene, which can be used as a favorable marker for clinical outcome.

Warnix will use the license in diagnostic applications such as patient stratification during clinical trials. The test may also help physicians with prognosis and monitoring patients for residual disease during chemotherapy.

Previous articleFDA Gives the Go-Ahead to Wyeth for Hemophilia A Therapy and Abbott for JIA Drug
Next articleGenetic Variation Linked to Increased Severity and Early Onset of Cystic Fibrosis